Clovis Oncology Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 0/6
Clovis Oncology has a total shareholder equity of $-417.9M and total debt of $660.4M, which brings its debt-to-equity ratio to -158%. Its total assets and total liabilities are $346.8M and $764.7M respectively.
Wichtige Informationen
-158.0%
Verhältnis von Schulden zu Eigenkapital
US$660.38m
Verschuldung
| Zinsdeckungsgrad | n/a |
| Bargeld | US$58.32m |
| Eigenkapital | -US$417.89m |
| Gesamtverbindlichkeiten | US$764.66m |
| Gesamtvermögen | US$346.78m |
Jüngste Berichte zur Finanzlage
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: CLVS.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langfristige Verbindlichkeiten: CLVS.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: CLVS.Q has negative shareholder equity, which is a more serious situation than a high debt level.
Schulden abbauen: CLVS.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilanz
Liquiditätsreserve-Analyse
Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.
Stabile Start- und Landebahn für Bargeld: Insufficient data to determine if CLVS.Q has enough cash runway based on its current free cash flow.
Vorhersage Cash Runway: Insufficient data to determine if CLVS.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.